*Disclaimer

INCANNEX HEALTHCARE LIMITED (ASX: IHL)

🔗 📄 📈

IHL: Fortrea to Manage IHL FDA IND Phase 2 and 3 Clinical Trial

INCANNEX HEALTHCARE LIMITED

2023-07-18 08:14:00

IHL: IHL Receives HREC Approval Ph 2 Clinical Trial for IHL675

INCANNEX HEALTHCARE LIMITED

2023-07-13 08:17:00

IHL: IHL Receives Ethics Approval BA/BE Clinical Trial.

INCANNEX HEALTHCARE LIMITED

2023-07-06 08:16:00

IHL: Principal Investigators Appointed for IHL42X Phase 2/3 Trial

INCANNEX HEALTHCARE LIMITED

2023-06-16 08:20:00

IHL: Lease Secured for Psychedelic Clinic

INCANNEX HEALTHCARE LIMITED

2023-05-05 08:47:00

IHL: Global CRO leader QPS engaged for CannQuit & ReneCann

INCANNEX HEALTHCARE LIMITED

2023-04-14 08:17:00

IHL: Incannex Launches Psychedelic Clinics Business

INCANNEX HEALTHCARE LIMITED

2023-03-16 10:01:00

IHL: Interim phase 2 PsiGAD psilocybin results

INCANNEX HEALTHCARE LIMITED

2023-03-15 10:04:00

IHL: Incannex to Manufacture Psilocybin for Trials & Commercial

INCANNEX HEALTHCARE LIMITED

2023-03-03 08:17:00

IHL: IHL Commences Phase 2 Clinical Trial

INCANNEX HEALTHCARE LIMITED

2023-02-28 09:19:00

IHL: Independent data review commences for Ph 2 trial psilocybin

INCANNEX HEALTHCARE LIMITED

  1. Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that the PsiGAD1 clinical trial, designed to assess Incannex’s psilocybin-assisted psychotherapy for the treatment of generalised anxiety disorder (“GAD”), has achieved its interim milestone of 29 patients completing primary endpoint assessments.
  2. Independent analysis of the interim study data has commenced and is expected to be completed in the coming weeks.
  3. The Company is encouraged by the progress of the trial and looks forward to sharing the results with stakeholders in due course.

2023-01-18 08:25:00